Autism Spectrum Disorder – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder involving significant social, communication, and behavioral challenges. Behavioral and developmental therapies are the cornerstones of treatment. There is no cure for ASD, and pharmacological intervention is mainly focused on symptomatic treatment of the disease. Risperidone and aripiprazole are the only two FDA-approved treatments to manage the irritability associated with ASD; other drugs are used off-label to manage co-occurring psychological conditions. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for ASD.
Questions answered
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed ASD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ASD patients?
- How have atypical antipsychotics been integrated into the treatment algorithm, and what is its source of business?
- What percentage of ASD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of ASD patients are treated with monotherapy versus combination therapy? What are the most widely used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients with ASD?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Janssen, Otsuka, Eli Lilly
Key drugs: Aripiprazole, fluoxetine, methylphenidate HCl, risperidone, sertraline
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
Ankita Ramnani, M.S., Associate Healthcare Research & Data Analyst, Infectious, Niche, and Rare Diseases. Prior to joining Clarivate, Ms. Ramnani was a regulatory affairs analyst for the Indian market at Dr. Reddy’s Laboratories, where she worked with cross-functional teams to address and resolve queries to India’s Central Drugs Standard Control Organization regarding licenses and NOC (no objection certificate) requirements. She holds a master’s degree in pharmaceutics from the National Institute of Pharmaceutical Education and Research in Mohali, India.